Tushar Pandey: From ITP to TTP in Clinical Practice
Tushar Pandey, Director and Head of Raghav Institute of Hematology, Hemato-Oncology and BMT at Raghav Healthcare, Editorial Board Member at Journal of Cancer Chemotherapy, Program Director of Hemato – Oncology at International Association For Integrated Oncology, shared a post on LinkedIn:
“Always a pleasure to speak about thrombocytopenia, especially ITP and TTP.
These conditions are commonly seen but still challenge clinicians due to their changing presentations, evolving evidence, and the need for timely and accurate decision-making.
From immune thrombocytopenia (ITP), where individualized treatment and long-term disease control are essential, to thrombotic thrombocytopenic purpura (TTP), a true hematologic emergency requiring rapid recognition and intervention, they reflect the complexity of real – world hematology practice.
Each opportunity like this helps bridge guidelines with real – life practice, ensuring patients receive evidence – based, practical, and life – saving care.
Grateful to contribute to the advancement of hematology, hemato-oncology, and BMT through knowledge sharing and clinical excellence.”
Stay updated with Hemostasis Today.
-
Jul 26, 2026, 16:26Novi Yanti Sari: When MPNs Affect the Heart
-
Jul 26, 2026, 16:21Beyond Drugs: Can Museums Become a Medical Prescription?
-
Jul 26, 2026, 14:45Sarah Giorgia Grazia Giannone: An Exciting Chapter in Gene Therapy Research
-
Jul 26, 2026, 14:21Javed Anees: Cerebral Collateral Circulation in Acute Ischemic Stroke
-
Jul 26, 2026, 14:11André Picard։ Canadian Blood Supplies Drop Sharply, Urgent Donor Appeal Issued
-
Jul 26, 2026, 13:54Lorenzo Scalia: New Review Highlights Anticoagulant Strategies for Elderly Patients With Atrial Fibrillation
-
Jul 26, 2026, 13:32Ahmed Kotb: A Practical Guide to Von Willebrand Disease
-
Jul 26, 2026, 12:42Emmanuel J Favaloro: Celebrating Excellence in Scientific Peer Review
-
Jul 26, 2026, 12:20Advancing Sickle Cell Care Through Advocacy – American Society of Hematology